Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
作者:
主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗体, 单克隆(Antibodies, Monoclonal);抗体, 单克隆, 鼠源性(Antibodies, Monoclonal, Murine-Derived);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);环磷酰胺(Cyclophosphamide);DNA结合蛋白质类(DNA-Binding Proteins);多柔比星(Doxorubicin);抗药性, 肿瘤(Drug Resistance, Neoplasm);女(雌)性(Female);人类(Humans);免疫组织化学(Immunohistochemistry);干扰素调节因子类(Interferon Regulatory Factors);Kaplan-Meiers评估(Kaplan-Meier Estimate);淋巴瘤, 大B细胞, 弥漫性(Lymphoma, Large B-Cell, Diffuse);男(雄)性(Male);中年人(Middle Aged);脑啡肽酶(Neprilysin);泼尼松(Prednisone);预后(Prognosis);原癌基因蛋白质c-bcl-2(Proto-Oncogene Proteins c-bcl-2);原癌基因蛋白质c-bcl-6(Proto-Oncogene Proteins c-bcl-6);长春新碱(Vincristine)
DOI
10.1111/j.1349-7006.2009.01268.x
PMID
19656156
发布时间
2024-06-09
- 浏览28

Cancer science
1842-7页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文